Can-fite BiopharmaCANF.AValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Can-fite Biopharma (CANF.A) trades at a negative P/E (-0.56x, due to a recent net loss), P/B of 1.10x, P/S of 13.20x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 3rd percentile over the trailing 10Y window (vs. 9th percentile over 3Y); P/S sits at the 28th percentile over the trailing 10Y window (vs. 25th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 25th percentile within its industry and the 33rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Can-fite Biopharma operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Want the full picture on whether Can-fite Biopharma (CANF.A) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -0.56 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.10 | ||||||
| P/S (TTM) | 13.20 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |